Background-Genome-wide association (GWA) studies have identified several susceptibility loci for metabolic syndrome (MetS) component traits, but have had variable success in identifying susceptibility loci to the syndrome as an entity. We conducted a GWA study on MetS and its component traits in 4 Finnish cohorts consisting of 2637 MetS cases and 7927 controls, both free of diabetes, and followed the top loci in an independent sample with transcriptome and nuclear magnetic resonance-based metabonomics data. Furthermore, we tested for loci associated with multiple MetS component traits using factor analysis, and built a genetic risk score for MetS. Methods and Results-A previously known lipid locus, APOA1/C3/A4/A5 gene cluster region (SNP rs964184), was associated with MetS in all 4 study samples (Pϭ7.23ϫ10 Ϫ9 in meta-analysis). The association was further supported by serum metabolite analysis, where rs964184 was associated with various very low density lipoprotein, triglyceride, and high-density lipoprotein metabolites (Pϭ0.024 -1.88ϫ10
undetected genetic loci may mediate clustering of MetS components, 9 -11 although some studies have failed to find unifying factors. 12, 13 More recently, the common genetic background hypothesis has been supported by emerging evidence of GWA loci where variants associate with more than 1 metabolic phenotype. 14 -16 
Clinical Perspective on p 249
Several candidate gene studies have analyzed MetS as a dichotomous trait using 1 of the available case control definitions, and successfully identified genes from specific pathways that are known to be relevant to MetS component phenotypes. 6 -8 In these, association with overall MetS status typically is explained by a strong association with 1 or 2 of the MetS components. The relatively few GWA studies, which have analyzed MetS status, have had variable success in identifying susceptibility loci. 5, 17, 18 The current evidence of MetS as an entity still is based mostly on clinical data on the component traits, and not on biological data connecting MetS susceptibility genes into pathways relevant to the broad spectrum of MetS components.
We searched for MetS susceptibility loci and evidence of a common genetic background for MetS by testing 4 types of associations: (1) individual single nucleotide polymorphisms (SNPs) and MetS (defined by the International Diabetes Federation [IDF]), 1 (2) SNPs and MetS component traits, (3) SNPs and MetS factors that combine evidence across component traits, and (4) MetS diagnosis and genetic risk score (GRS) derived from loci associated with 1 or more component traits of MetS.
Methods
Each of the DNA donors in our study has given individual consent to the use of their DNA sample in scientific research. The studies have been approved by the relevant research ethics boards.
Study Subjects
Four Finnish population cohorts were included in the study sample (Table) . We used the IDF definition of metabolic syndrome 1 to identify cases and controls (Table; see online-only Data Supplement  Tables SI and SII , and Figure SI) . In all, our study included 11 616 subjects, from which 23% fulfilled criteria for MetS cases (Nϭ2637) and 68% for controls (Nϭ7927). Our replication study samples in the GRS analysis consisted of 906 nondiabetic men from the Metabolic Syndrome in Men (METSIM) study population, 19 
Genome-Wide Association Analyses
Using directly measured and imputed genotypes in logistic or linear regression analysis, we tested for association between SNPs and MetS (and quantitative MetS component traits) in each study separately using PLINK version 1.07 23 for directly genotyped SNPs, and ProbABEL version 0.1-6 24 for imputed SNPs, and then combined the results in a genome-wide fixed effects meta-analysis across all samples (2637 cases and 7927 controls, after excluding individuals with diabetes) with Metabel version 0.03, applying genomic control correction to each GWA data before pooling. 25 We computed (based on ␤-estimates and standard error) I 2 statistics as measures of heterogeneity between studies. We adjusted the analyses for age (except in NFBC1966) and gender, and used an additive model for the SNP effect. In MetS component trait analyses, individuals taking hypolipidemic, antihypertensive, or hypoglycaemic medication were not included in the relevant trait analyses (see online-only Data Supplement for details and power calculations).
Copy Number Polymorphism Tag-Single Nucleotide Polymorphism Analysis
We extended our genetic analysis from single nucleotides to structural variation by assessing the association between previously identified genomic copy number polymorphisms (CNPs) and MetS. For this, we had directly genotyped or imputed genotypes for 620 SNPs that were in linkage disequilibrium with CNPs and could be used as proxies for the CNP alleles of 649 CNPs in our data. All GWA analyses for these CNP tag-SNPs were done as part of the main SNP GWA analysis (see online-only Data Supplement).
Single Nucleotide Polymorphism Associations With Gene Expression and Serum Metabolites
Expression quantitative trait locus and serum metabolite data were available from an independent study sample of 518 Finns. A total of 135 metabolic measures were obtained from nuclear magnetic resonance spectroscopy data of both native serum and lipid extracts (see online-only Data Supplement).
Risk Score Analysis
We selected for the GRS analysis the SNP with the strongest statistical evidence (lowest probability value) of an association with any MetS component trait from each of the 22 genome-wide significant loci (see online-only Data Supplement Table SIII) . We then formed and evaluated the GRS using 2 independent cohorts by calculating the average number of risk increasing alleles of each variant for each study individual and divided our study samples into quartiles based on the GRS distribution, separately for each study sample. We compared the risk of MetS in these quartiles in an age and gender adjusted logistic regression model in R, 26 using the lowest quartile as a reference group (see online-only Data Supplement). Albeit, for example, for cardiovascular diseases it would be relatively easy to compare the effect of GRS and conventional risk factors for an association with a disease, a difficulty in the case of MetS arises from the definition of the syndrome; the definition itself already includes many conventional risk factors such as dyslipidemia, central obesity, hypertension, and insulin resistance. For this reason, we assessed the value of our GRS for the risk of MetS in a simple model adjusted for age and gender only.
Factor Analysis
Factor analysis has been applied to MetS in several studies with the aim to identify unifying entities (factors) for the same quantitative MetS component traits that were analyzed individually (see online-only Data Supplement). We estimated factor loadings (see online-only Data Supplement Table SIV) based on correlations of individual MetS components and created factor scores as linear combinations based on 3 factor solutions: (1) lipids/waist circumference, (2) lipids/waist circumference/insulin resistance (HOMA-IR), and (3) systolic (SBP) and diastolic (DBP) blood pressure. Factor scores were analyzed as quantitative traits similarly to the individual MetS component traits (see online-only Data Supplement). Individuals taking hypolipidemic, antihypertensive, or hypoglycaemic medication were not included in the relevant factor analyses.
Results

Metabolic Syndrome, Case Control Analysis
Our study sample of 11 616 nondiabetic Finnish individuals comprised 4 GWA scans (2637 cases and 7927 controls by IDF criteria of MetS; Table 1 ). We conducted the 4 GWA analyses and their meta-analysis using 1 257 079 directly genotyped or imputed SNPs. In meta-analysis of the 4 data sets, the minor allele of SNP rs964184, on chromosome 11q23.3 in a known lipid locus, apolipoprotein APOA1/C3/ A4/A5 gene cluster region, was associated with increased risk for MetS (Pϭ7.23ϫ10
Ϫ9 ; see online-only Data Supplement Figures SII and SIII) . The associations were to the same direction in all 4 study samples ( Figure 1) , with an overall effect size odds ratio (OR) of 1.33 (95% CI, 1.20 -1.46). Five SNPs that are associated with MetS in a recent GWA study 5 were not replicated on a genome-wide significance level in our data, although a meta-analysis combining both studies found these SNPs highly significant (see online-only Data Supplement Table SV) .
In parallel to the complete GWA scan, we analyzed a subset of the SNPs (Nϭ620) as CNP tag-SNPs, to test for an association between MetS and structural variation in the genome. Pooling results from all 4 data sets failed to identify significant associations between MetS and genomic loci. Some of the GWA top hit SNPs associated with more than 1 MetS related phenotype (Figure 2) . Several of the established lipid loci SNPs associated with HDL, TG, MetS, and the factors F1 and F2 (containing lipids, waist, and insulin resistance [HOMA-IR]) from the factor analysis. A few loci also showed suggestive association with waist circumference, HOMA-IR, and the factors F1 and F2. The glucose and SBP associated GWA SNPs did not show association with other phenotypes. These SNP associations with phenotypes were in concordance with correlations between those phenotypes in our data (see online-only Data Supplement Results and Figure SV ). An exception to this association and correlation pattern was observed for the GCKR gene locus SNP rs780094, which had a strong positive association with TG and the TG/HDL/waist circumference-factor, but at the same time had suggestive negative associations with glucose and HOMA-IR.
Dissecting the Underlying Mechanism of the Associations With Metabolic Syndrome
We examined the underlying factors of our MetS association by studying the association between the relevant SNP rs964184 and the component traits that were used to define the case control status. Rs964184 was associated with TG (Pϭ2.59ϫ10 Ϫ31 ) and HDL (Pϭ5.83ϫ10 Ϫ8 ), but not with waist circumference (Pϭ0.52), SBP (Pϭ0.68), DBP (Pϭ0.98), or glucose (Pϭ0.73). When we adjusted the case control analysis for TG or HDL, the association of rs964184 disappeared (Pϭ0.41 with TG and HDL in the model, Pϭ0.62 with TG in the model) or was reduced (Pϭ0.0017 with HDL in the model). This suggested that the main driving force behind the case control association signal of rs964184 was its association with lipid components of MetS.
We proceeded to analyze metabolome and transcriptome data from an independent Finnish study sample of 518 individuals. The association analysis of rs964184 and 135 metabolites supported the conclusion that lipid components were behind the MetS association; rs964184 was associated with several metabolites, most significantly with all 30 of the very low density lipoprotein particles (Pϭ0.024 -1.88ϫ10
Ϫ5 , Bonferroni corrected probability value cut-off for significance P sig ϭ3.70ϫ10 Ϫ4 ). Other significant and suggestive associations included, unsurprisingly, TG metabolites (see online-only Data Supplement Results). We also examined ). None of these 5 MetS SNPs were associated with glucose or glycoproteins (PϾ0.14).
Our leukocyte-derived gene expression data analysis failed to identify any cis-or transregulated genes whose expression was significantly affected by the rs964184 alleles, possibly due to differential lipid gene expression in leukocytes and other more relevant tissues, such as fat or liver, and a relatively small number of samples analyzed (see online-only Data Supplement Results).
Metabolic Syndrome, Risk Score Analysis
We extended our GWA analysis to the individual components of the MetS phenotype: waist circumference, TG, and HDL levels, SBP, DBP, and fasting plasma glucose. We observed SNP associations with HDL, TG, and glucose concentrations at the genome-wide significance level in several previously identified gene loci (see online-only Data Supplement Figure  SVI) . We then proceeded to test how GRS, combined with age and gender, would help to identify individuals with a high risk of developing MetS. We created a GRS using the 22 risk variants that were associated with the 5 IDF MetS component traits at a genome-wide significance level in our study (see online-only Data Supplement Figure SVI ) and assigned study subjects to GRS quartiles based on the number of risk alleles they carried (see online-only Data Supplement Table SVI and Figure SVII ). The risk of MetS increased linearly across quartiles in the combined data of the 4 cohorts (P for linear trendϭ6.91ϫ10 Ϫ11 ). Odds ratio for the risk of MetS in the highest GRS quartile compared with the lowest GRS quartile was 1.55 (95% CI, 1.35-1.77; see online-only Data Supplement Table SVI) . We replicated our GRS analysis in a meta-analysis of 2 independent study cohorts: an independent study sample of 906 nondiabetic men (METSIM study 19 ) and 611 study subjects from the FINRISK 2007 study. 20 The OR for the risk of MetS in the highest GRS quartile compared with the lowest quartile was 1.35 (Pϭ0.045; GRS/Q2: OR, 1.17, 95% CI, 0.88 -1.56; GRS/Q3: OR, 1.33, 95% CI, 0.98 -1.80; GRS/Q4: OR, 1.35, 95% CI, 1.01-1.82).
We conducted another GRS analysis using the 5 MetS SNPs reported by the STAMPEED Consortium 5 (see onlineonly Data Supplement Table SV 
Discussion
Our GWA study of metabolic syndrome identified an association between MetS diagnosis and a previously known lipid locus APOA1/C3/A4/A5 gene cluster region on chromosome 11. 5, 16, 27, 28 The risk effect of SNP rs964184 in our study was consistent across our cohorts, which have very different age profiles. Our GWA and serum metabolite data suggested that the SNP effect was mainly on the lipid component of MetS, which also was recently suggested in a metabolite analysis of another cohort of European ancestry. 29 This lipid-driven association is somewhat surprising considering that our data included 650 individuals who met the MetS case criteria only because of high glucose level and hypertension, compared with only 169 individuals who were identified as cases solely due to abnormal TG and HDL levels. The 5 SNPs recently reported to associate with MetS by the STAMPEED Consortium 5 also associated with several lipid metabolites, and not with glucose, in our metabolite analysis.
Identification of novel genetic loci harboring genes that simultaneously affect several MetS component traits would provide important clues to the biological background of MetS as a whole and not merely a sum of the component traits, and may aid in genetic risk prediction of MetS. Our factor analysis and GWA SNP results identified many gene loci associated with the lipid components of MetS and MetS phenotype factors that included waist and HOMA-IR, but were strongly based on HDL and TG. Glucose and blood pressure SNP associations seemed to be somewhat separate from these lipid-driven associations. The GCKR gene (glucokinase [hexokinase 4] regulator) region was an interesting exception; its minor allele (A/T) associated with higher TG levels and lower HOMA-IR. This result is supported by previous observations; SNP rs780094 T-allele has been associated with increased TG levels, 30, 31 and the major allele C with higher glucose and insulin levels and HOMA-IR. 15, 30, 31 Although our relatively small metabolite data supported only the TG association of rs780094, it is likely that the gene has an effect, seemingly an opposite one, on both TG and insulin traits. This opposing effect may contribute to the lack of association between GCKR and MetS status in our data. On the whole, our factor analysis supported the GWA SNP results, indicating that there was little evidence for connections between the blood pressure and lipid/waist, and glucose components of MetS.
Our genetic risk score analysis suggested that combining genetic association information across the MetS component traits can help in identifying individuals with a higher genetic susceptibility for developing MetS. Using information from the several individual MetS component trait associations to build a GRS seemed to give better results than building a GRS using a smaller number of loci of MetS case control association from a previous study. 5 Extensive research is, however, needed before any GRS can be used in clinical practice.
The exclusion of diabetic individuals can be seen both as a strength and a limitation of this study. Because people with diagnosed diabetes usually are treated with several drugs or insulin, we reduce the variation among cases by excluding the individuals with a diagnosis of diabetes. At the same time these excluded individuals may have a genetic predisposition to insulin resistance, which limits our analysis of MetS component traits of glucose and HOMA-IR. In our tests, additional novel SNP associations with MetS were not observed after including diabetic individuals in the analysis. Another possible limitation in our study is the sample size (Nϭ11 616) when compared with some of the current GWA studies that are using an even larger number of subjects (Ͼ100 000). In all probability, however, not all previously undetected susceptibility loci are uncovered merely by increasing the sample size. Here, we aimed to eliminate some of the obscuring factors in gene identification by using a culturally homogenous and genetically unique population. 32, 33 We had 4 independent study samples enabling comparison of the results between data sets and meta-analysis. In addition, a moderate portion of our sample is rather young, in terms of a late-onset syndrome such as MetS and its component traits, 34 and thus individuals diagnosed with MetS may have a stronger genetic component and less environmental factors masking the effect of genes, which may aid in unearthing the genetic susceptibility loci. Due to our homogenous population, any generalization of the results has to be made cautiously.
Conclusion
As a whole, our GWAS, factor analysis, and serum metabolome analysis revealed a strong lipid gene contribution to the observed MetS associations and showed little evidence for pleiotropy, linking dyslipidemia and obesity to the other types of metabolic abnormalities: glucose intolerance and hypertension. We thus conclude that there are probably no gene variants predisposing to the metabolic syndrome by affecting multiple components of its definition that have a clinically relevant effect size. Our findings suggest that the genetic predisposition to MetS is likely to result from relatively small effects of multiple genes predisposing to dyslipidemia and abdominal obesity, possibly complemented by low frequency and rare variation or epigenetic modifications. From a clinical point of view it thus may make more sense to study the individual component traits instead of MetS as an entity, and to direct efforts especially to the lipid components that seemed to play the key role in our study.
